Bill > S3267

This bill amends the Social Security Act to add Medicare coverage for blood-based screening tests designed to detect early stages of Alzheimer's disease and related dementias, starting January 1, 2028. Specifically, the bill defines these screening tests as medical procedures that are either genomic sequencing blood tests or other equivalent tests (such as blood analysis of cell-free nucleic acids, multiplex panel tests, whole genome sequencing, protein expression tests, whole exome or transcriptome tests, and medical imaging) that have been cleared, classified, or approved by the Federal Food, Drug, and Cosmetic Act. The tests must be capable of detecting pre-symptomatic and early-stage Alzheimer's or related dementias. By adding these tests to Medicare's covered services, the bill aims to improve early detection of these conditions, potentially allowing for earlier intervention and treatment. The legislation, known as the ASAP Act (Alzheimer's Screening and Prevention Act), will enable Medicare to reimburse healthcare providers for administering these advanced screening tests to eligible individuals.

Budget and Finance

https://www.congress.gov/bill/119th-congress/senate-bill/3267/all-info